235. 副甲状腺機能低下症 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 100 / 薬物数 : 103 - (DrugBank : 27) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 7
薬物、開発者(Primary Sponsor)、臨床試験情報(症例登録開始年(Enrollment year)、フェーズ、ID、実施国)
200-1600 µG OF MBX 2109 ONCE-weekly BY subcutaneous injection
MBX Biosciences
2024 Phase 2 NCT06531941 United States
400 µG OF MBX 2109 ONCE-weekly BY subcutaneous injection
MBX Biosciences
2024 Phase 2 NCT06531941 United States
Acetate
Hospital Italiano de Buenos Aires
2016 Phase 4 NCT02652884 Argentina
Alfacalcidol
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 2 EUCTR2016-000500-29-FR France
Assistance Publique - Hôpitaux de Paris
2017 Phase 2 NCT02824718 France
Allogenic parathyroid cells
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
2022 Phase 1/Phase 2 NCT05186883 -
AMOR-1
Amorphical Ltd.
2024 Phase 2 NCT06547151 Israel
Amorphous calcium carbonate
Amorphical Ltd.
2013 - NCT06288490 Israel
2013 Phase 1/Phase 2 NCT01815021 Israel
Autofluorescent detection + injection OF indocyanine green
Onze Lieve Vrouw Hospital
2021 Phase 3 NCT05117853 Belgium
AZP-3601
Amolyt Pharma
2020 Phase 1 NCT05239221 Hungary;Netherlands
Betamethasone
Hospital Italiano de Buenos Aires
2016 Phase 4 NCT02652884 Argentina
Blood sample
Hospices Civils de Lyon
2021 - NCT04671719 France
Calcitriol
Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
2021 Phase 1-2 ChiCTR2100041719 China
Calcitriol & calcium
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
1991 Phase 2 NCT00001304 United States
Calcium
Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
2021 Phase 1-2 ChiCTR2100041719 China
West China Hospital, Sichuan University
2019 - ChiCTR1900022194 China
Calcium carbonate
Campus Bio-Medico University
2019 Phase 4 NCT03425747 Italy
Hokusetsu ROD Study Group
2006 - JPRN-UMIN000000475 Japan
Calcium carbonate and alphacalcidol
University of Athens
2017 - NCT04146259 Greece
Calcium citrate
Campus Bio-Medico University
2019 Phase 4 NCT03425747 Italy
Calcium gluconate
National Center for Research Resources (NCRR)
1995 - NCT00004361 -
Calcium lactate
kawasaki medicak school
2009 Phase 3 JPRN-UMIN000002155 Japan
Carbon
The Sixth Medical Center of PLA General Hospital
2020 Phase 0 ChiCTR2300077263 China
CLTX-305
National Institute of Dental and Craniofacial Research (NIDCR)
2020 Phase 2 NCT04465227 United States
Crystalline calcium carbonate
Amorphical Ltd.
2024 Phase 2 NCT06547151 Israel
Crystalline calcium supplements
Amorphical Ltd.
2013 Phase 1/Phase 2 NCT01815021 Israel
Dexamethasone
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
EBP05
Entera Bio Ltd.
2023 Phase 1/Phase 2 NCT05965167 Israel
2018 Phase 2 NCT03516773 Israel
EBP11
Entera Bio Ltd.
2023 Phase 1/Phase 2 NCT05965167 Israel
EBP22
Entera Bio Ltd.
2023 Phase 1/Phase 2 NCT05965167 Israel
Empiric USE OF calcium carbonate and calcitriol
CHU de Quebec-Universite Laval
2017 - NCT03249012 Canada
Encaleret
National Institute of Dental and Craniofacial Research (NIDCR)
2023 Phase 2 NCT05735015 United States
Eneboparatide
Amolyt Pharma
2023 Phase 3 NCT05778071 Canada;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Portugal;Spain;United Kingdom;United States
Esidrex-R 25 MG
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 2 EUCTR2016-000500-29-FR France
Ether
Ascendis Pharma Bone Disease A/S
2021 Phase 3 EUCTR2020-003380-26-IT Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
Ascendis Pharma Bone Diseases A/S
2021 Phase 3 EUCTR2020-003380-26-FR Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-GB Canada;Denmark;Germany;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DK Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DE Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Forsteo
Dipartimento di Medicina e Chirurgia Traslazionale dell’Università degli Studi di Firenze
2014 Phase 3 EUCTR2013-001890-26-IT Italy
Forsteo-R
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 2 EUCTR2016-000500-29-FR France
Forteo 20 MG
Entera Bio Ltd.
2023 Phase 1/Phase 2 NCT05965167 Israel
Human recombinant parathyroid hormone
Shire Human Genetic Therapies, Inc.
2018 Phase 3 EUCTR2017-003067-36-HU Canada;Denmark;Hungary;United States
2018 Phase 3 EUCTR2017-003067-36-DK Canada;Denmark;Hungary;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-SE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-PT Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-NO Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-ES Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-DK Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-BE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
Hydrochlorothiazide
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 2 EUCTR2016-000500-29-FR France
ICG
University Hospital, Brest
2021 Phase 3 NCT04785443 France
Immediate post operative bioassay OF parathyroid hormone
Centre Hospitalier Universitaire de Nimes
2012 - NCT02924532 -
Indocyanine green
Hospital Son Espases
2016 Phase 4 NCT04012476 Spain
Hospital Universitari Son Espases
2020 Phase 4 EUCTR2019-003506-26-ES Spain
IRCCS San Raffaele
2022 - NCT05328076 Italy
Indocyanine green near infrared fluorescence imaging
University Medical Center Groningen
2020 Early Phase 1 NCT06579430 Netherlands
Infracyanine
CHRU de Brest
2021 Phase 3 EUCTR2020-005189-32-FR France
INN parathyroid hormone (1-84) human
NPS Pharmaceuticals, Inc.
2015 Phase 1 EUCTR2015-003108-22-GB United Kingdom
Magnesium
University of Tartu
2009 - NCT00824226 Estonia
MBX 2109
MBX Biosciences
2024 Phase 2 NCT06465108 Argentina;United States
Methylene blue
The Sixth Medical Center of PLA General Hospital
2020 Phase 0 ChiCTR2300077263 China
Natpar
Shire Human Genetic Therapies, Inc.
2018 Phase 3;Phase 4 EUCTR2017-000284-32-SE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-PT Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-NO Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-DK Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-BE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
Natpara
Shire Human Genetic Therapies, Inc.
2018 Phase 3 EUCTR2017-003067-36-HU Canada;Denmark;Hungary;United States
2018 Phase 3 EUCTR2017-003067-36-DK Canada;Denmark;Hungary;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-IT Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-ES Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
Natpara/natpar
Entera Bio Ltd.
2018 Phase 2 NCT03516773 Israel
NEAR-infrared-induced autofluorescence and indocyanine green NEAR-infrared angiography
Odense University Hospital
2021 - NCT05130476 Denmark
Npsp 558
NPS PHARMACEUTICALS
2009 - EUCTR2008-005063-34-IT Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
NPS Pharmaceuticals, Inc.
2015 Phase 1 EUCTR2015-003108-22-GB United Kingdom
2011 - EUCTR2011-001265-40-HU Hungary
2010 - EUCTR2008-005063-34-LT Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2010 - EUCTR2008-005063-34-HU Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2009 Phase 3 EUCTR2008-005063-34-GB Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2009 Phase 3 EUCTR2008-005063-34-FR Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2009 - EUCTR2008-005063-34-DK Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2008 Phase 3 EUCTR2008-005063-34-BE Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
NPSP558
Shire
2011 Phase 3 NCT01455181 Hungary
2011 Phase 3 NCT01297309 United States
2011 Phase 3 NCT01268098 United States
2008 Phase 3 NCT00732615 Belgium;Canada;Denmark;France;Hungary;Italy;United Kingdom;United States
Ormone paratiroideo DA DNA ricombinante
Shire Human Genetic Therapies, Inc.
2018 Phase 3;Phase 4 EUCTR2017-000284-32-IT Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
Oxygen
Chongqing People's Hospital
2023 - ChiCTR2300076192 China
Palopegteriparatide
Ascendis Pharma Bone Diseases A/S
2022 - NCT05654701 -
2021 Phase 3 EUCTR2020-003380-26-HU Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2021 Phase 3 EUCTR2020-003380-26-DK Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2021 Phase 3 EUCTR2020-003380-26-DE Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2020 Phase 3 EUCTR2020-003380-26-NO Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-NO Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DK Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Parathyroid allotransplant
Peter Stock
2025 Phase 1/Phase 2 NCT06961071 United States
Parathyroid hormon 1-84
University of Bergen
2016 Early Phase 1 NCT02986607 Norway
Parathyroid hormone
Aarhus University Hospital, Dept of Endocrinology and Metabolism C
2008 Phase 4 EUCTR2008-000606-36-DK Denmark
Entera Bio Ltd.
2014 Phase 2 NCT02152228 Israel
NPS Pharmaceuticals, Inc.
2011 - EUCTR2011-001265-40-HU Hungary
2010 - EUCTR2008-005063-34-LT Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2010 - EUCTR2008-005063-34-HU Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2009 Phase 3 EUCTR2008-005063-34-GB Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2009 Phase 3 EUCTR2008-005063-34-FR Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2009 - EUCTR2008-005063-34-DK Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2008 Phase 3 EUCTR2008-005063-34-BE Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
Takeda Pharmaceutical Company Limited
2022 Phase 3 JPRN-jRCT2080224751 Japan
Parathyroid hormone (1-84) human recombinant
NPS Pharmaceuticals, Inc.
2015 Phase 1 EUCTR2015-003108-22-GB United Kingdom
Parathyroideahormon
Aarhus University Hospital, Dept of Endocrinology and Metabolism C
2008 Phase 4 EUCTR2008-000606-36-DK Denmark
PCO371
Chugai Pharmaceutical
2020 Phase 1 NCT04209179 Canada;Hungary;United States
Phosphate
Hokusetsu ROD Study Group
2006 - JPRN-UMIN000000475 Japan
Hospital Italiano de Buenos Aires
2016 Phase 4 NCT02652884 Argentina
Poly(OXY-1,2-ethanediyl), alpha-hydro-omega-methoxy, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-DI
Ascendis Pharma Bone Diseases A/S
2021 Phase 3 EUCTR2020-003380-26-HU Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2021 Phase 3 EUCTR2020-003380-26-DK Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2021 Phase 3 EUCTR2020-003380-26-DE Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2020 Phase 3 EUCTR2020-003380-26-NO Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
Poly(OXY-1,2-ethanediyl), alpha-hydro-omega-methoxy, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbon
Ascendis Pharma Bone Diseases A/S
2019 Phase 2 EUCTR2018-004815-33-NO Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Postoperative laboratory blood tests AT 24 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Postoperative laboratory blood tests AT 6 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Postoperative laboratory drainage fluid tests AT 24 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Postoperative nausea and vomiting AT 24 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Postoperative nausea and vomiting AT 6 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Postoperative pain AT 24 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Postoperative pain AT 6 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Postoperative sore throat and hoarseness AT 24 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Postoperative sore throat and hoarseness AT 6 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Potassium sparing diuretic
Assistance Publique - Hôpitaux de Paris
2017 Phase 2 NCT02824718 France
Preoparative blood laboratory tests
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Preotact
Aarhus University Hospital, Dept of Endocrinology and Metabolism C
2008 Phase 4 EUCTR2008-000606-36-DK Denmark
NPS Pharmaceuticals, Inc.
2011 - EUCTR2011-001265-40-HU Hungary
2010 - EUCTR2008-005063-34-LT Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
PTH
Columbia University
2009 Phase 3 NCT01199614 United States
John P. Bilezikian
2004 Phase 2/Phase 3 NCT00473265 United States
Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
2021 Phase 1-2 ChiCTR2100041719 China
University of Aarhus
2008 Phase 2 NCT00730210 Denmark
kawasaki medicak school
2009 Phase 3 JPRN-UMIN000002155 Japan
PTH 1-34
National Institute of Dental and Craniofacial Research (NIDCR)
2006 Phase 3 NCT00395538 Austria;Italy;United States
PTH based calcium carbonate and calcitriol repletion
CHU de Quebec-Universite Laval
2017 - NCT03249012 Canada
PTH1-84 IN parent study
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2010 Phase 3 NCT00856401 United States
Rhpth
NPS Pharmaceuticals, Inc.
2011 - EUCTR2011-001265-40-HU Hungary
2010 - EUCTR2008-005063-34-LT Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2010 - EUCTR2008-005063-34-HU Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2009 Phase 3 EUCTR2008-005063-34-GB Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2009 Phase 3 EUCTR2008-005063-34-FR Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2009 - EUCTR2008-005063-34-DK Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2008 Phase 3 EUCTR2008-005063-34-BE Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
Shire
2022 Phase 3 NCT03878953 Japan
2018 Phase 3 NCT03364738 Canada;Denmark;Hungary;United States
2018 Phase 4 NCT03324880 Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2017 Phase 1 NCT03150108 United States
2017 Phase 1 NCT02781844 Canada;Denmark;Hungary;United States
2016 Phase 4 NCT02910466 United States
Shire Human Genetic Therapies, Inc.
2018 Phase 3 EUCTR2017-003067-36-HU Canada;Denmark;Hungary;United States
2018 Phase 3 EUCTR2017-003067-36-DK Canada;Denmark;Hungary;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-SE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-PT Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-NO Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-ES Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-DK Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-BE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
Takeda Pharmaceutical Company Limited
2022 Phase 3 JPRN-jRCT2080224751 Japan
Saline 0.9% nacl
Hospital Italiano de Buenos Aires
2016 Phase 4 NCT02652884 Argentina
Serum calcium concentrations results
Hospices Civils de Lyon
2019 - NCT04126941 France
Sevelamer
Hokusetsu ROD Study Group
2006 - JPRN-UMIN000000475 Japan
Sodium citrate
National Center for Research Resources (NCRR)
1995 - NCT00004361 -
Standard treatment according TO THE clinical protocols
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
2022 Phase 1/Phase 2 NCT05186883 -
SUB21634
Aarhus University Hospital, Dept of Endocrinology and Metabolism C
2008 Phase 4 EUCTR2008-000606-36-DK Denmark
Symptomatic hypocalcaemia AT 24 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Symptomatic hypocalcaemia AT 6 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Synthetic human parathyroid hormone 1-34
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2008 Phase 2 NCT00743782 United States
1991 Phase 2 NCT00001304 United States
Teriparatide
Ascendis Pharma Bone Diseases A/S
2021 Phase 3 EUCTR2020-003380-26-HU Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2021 Phase 3 EUCTR2020-003380-26-DK Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2021 Phase 3 EUCTR2020-003380-26-DE Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2020 Phase 3 EUCTR2020-003380-26-NO Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-NO Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DK Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Assistance Publique - Hôpitaux de Paris
2017 Phase 2 NCT02824718 France
Dipartimento di Medicina e Chirurgia Traslazionale dell’Università degli Studi di Firenze
2014 Phase 3 EUCTR2013-001890-26-IT Italy
Mayo Clinic
2010 Phase 2 NCT01171690 United States
Saint Petersburg State University, Russia
2021 Phase 3 NCT04750460 Russian Federation
The Seventh Medical Center, PLA General Hospital
2021 - ChiCTR2100047758 China
Teriparatide conjugated TO A multiarm polyethylene glycol carrier molecule through A cleava
Ascendis Pharma Bone Diseases A/S
2021 Phase 3 EUCTR2020-003380-26-FR Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
Teriparatide conjugated TO A multiarm polyethylene glycol carrier molecule through A cleavable linker
Ascendis Pharma Bone Disease A/S
2021 Phase 3 EUCTR2020-003380-26-IT Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-IT Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Ascendis Pharma Bone Diseases A/S
2021 Phase 3 EUCTR2020-003380-26-FR Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-GB Canada;Denmark;Germany;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DE Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Thiazide
Assistance Publique - Hôpitaux de Paris
2017 Phase 2 NCT02824718 France
Thymus/parathyroid transplantation
M. Louise Markert
2005 Phase 1 NCT00566488 United States
Total thyroidectomy
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Transcon PTH
Ascendis Pharma Bone Diseases A/S
2022 - NCT05654701 -
2021 Phase 3 EUCTR2020-003380-26-HU Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2021 Phase 3 EUCTR2020-003380-26-FR Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2021 Phase 3 EUCTR2020-003380-26-DK Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2021 Phase 3 EUCTR2020-003380-26-DE Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2020 Phase 3 EUCTR2020-003380-26-NO Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
Visen Pharmaceuticals (Shanghai) Co., Ltd.
2021 Phase 3 NCT05387070 China
Transcon PTH HIGH-dose PEN
Ascendis Pharma Bone Disease A/S
2021 Phase 3 EUCTR2020-003380-26-IT Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-IT Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Ascendis Pharma Bone Diseases A/S
2019 Phase 2 EUCTR2018-004815-33-NO Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-GB Canada;Denmark;Germany;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DK Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DE Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Transcon PTH LOW-dose PEN
Ascendis Pharma Bone Disease A/S
2021 Phase 3 EUCTR2020-003380-26-IT Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-IT Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Ascendis Pharma Bone Diseases A/S
2019 Phase 2 EUCTR2018-004815-33-NO Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-GB Canada;Denmark;Germany;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DK Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DE Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Transcon PTH MID-dose PEN
Ascendis Pharma Bone Disease A/S
2021 Phase 3 EUCTR2020-003380-26-IT Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-IT Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Ascendis Pharma Bone Diseases A/S
2019 Phase 2 EUCTR2018-004815-33-NO Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-GB Canada;Denmark;Germany;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DK Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DE Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Tériparatide
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 2 EUCTR2016-000500-29-FR France
UN-alpha-R 0.25µG
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 2 EUCTR2016-000500-29-FR France
Vitamin D
University of Wisconsin, Madison
2005 Phase 4 NCT00581828 United States
West China Hospital, Sichuan University
2019 - ChiCTR1900022194 China
MBX Biosciences
2024 Phase 2 NCT06531941 United States
400 µG OF MBX 2109 ONCE-weekly BY subcutaneous injection
MBX Biosciences
2024 Phase 2 NCT06531941 United States
Acetate
Hospital Italiano de Buenos Aires
2016 Phase 4 NCT02652884 Argentina
Alfacalcidol
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 2 EUCTR2016-000500-29-FR France
Assistance Publique - Hôpitaux de Paris
2017 Phase 2 NCT02824718 France
Allogenic parathyroid cells
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
2022 Phase 1/Phase 2 NCT05186883 -
AMOR-1
Amorphical Ltd.
2024 Phase 2 NCT06547151 Israel
Amorphous calcium carbonate
Amorphical Ltd.
2013 - NCT06288490 Israel
2013 Phase 1/Phase 2 NCT01815021 Israel
Autofluorescent detection + injection OF indocyanine green
Onze Lieve Vrouw Hospital
2021 Phase 3 NCT05117853 Belgium
AZP-3601
Amolyt Pharma
2020 Phase 1 NCT05239221 Hungary;Netherlands
Betamethasone
Hospital Italiano de Buenos Aires
2016 Phase 4 NCT02652884 Argentina
Blood sample
Hospices Civils de Lyon
2021 - NCT04671719 France
Calcitriol
Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
2021 Phase 1-2 ChiCTR2100041719 China
Calcitriol & calcium
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
1991 Phase 2 NCT00001304 United States
Calcium
Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
2021 Phase 1-2 ChiCTR2100041719 China
West China Hospital, Sichuan University
2019 - ChiCTR1900022194 China
Calcium carbonate
Campus Bio-Medico University
2019 Phase 4 NCT03425747 Italy
Hokusetsu ROD Study Group
2006 - JPRN-UMIN000000475 Japan
Calcium carbonate and alphacalcidol
University of Athens
2017 - NCT04146259 Greece
Calcium citrate
Campus Bio-Medico University
2019 Phase 4 NCT03425747 Italy
Calcium gluconate
National Center for Research Resources (NCRR)
1995 - NCT00004361 -
Calcium lactate
kawasaki medicak school
2009 Phase 3 JPRN-UMIN000002155 Japan
Carbon
The Sixth Medical Center of PLA General Hospital
2020 Phase 0 ChiCTR2300077263 China
CLTX-305
National Institute of Dental and Craniofacial Research (NIDCR)
2020 Phase 2 NCT04465227 United States
Crystalline calcium carbonate
Amorphical Ltd.
2024 Phase 2 NCT06547151 Israel
Crystalline calcium supplements
Amorphical Ltd.
2013 Phase 1/Phase 2 NCT01815021 Israel
Dexamethasone
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
EBP05
Entera Bio Ltd.
2023 Phase 1/Phase 2 NCT05965167 Israel
2018 Phase 2 NCT03516773 Israel
EBP11
Entera Bio Ltd.
2023 Phase 1/Phase 2 NCT05965167 Israel
EBP22
Entera Bio Ltd.
2023 Phase 1/Phase 2 NCT05965167 Israel
Empiric USE OF calcium carbonate and calcitriol
CHU de Quebec-Universite Laval
2017 - NCT03249012 Canada
Encaleret
National Institute of Dental and Craniofacial Research (NIDCR)
2023 Phase 2 NCT05735015 United States
Eneboparatide
Amolyt Pharma
2023 Phase 3 NCT05778071 Canada;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Portugal;Spain;United Kingdom;United States
Esidrex-R 25 MG
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 2 EUCTR2016-000500-29-FR France
Ether
Ascendis Pharma Bone Disease A/S
2021 Phase 3 EUCTR2020-003380-26-IT Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
Ascendis Pharma Bone Diseases A/S
2021 Phase 3 EUCTR2020-003380-26-FR Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-GB Canada;Denmark;Germany;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DK Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DE Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Forsteo
Dipartimento di Medicina e Chirurgia Traslazionale dell’Università degli Studi di Firenze
2014 Phase 3 EUCTR2013-001890-26-IT Italy
Forsteo-R
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 2 EUCTR2016-000500-29-FR France
Forteo 20 MG
Entera Bio Ltd.
2023 Phase 1/Phase 2 NCT05965167 Israel
Human recombinant parathyroid hormone
Shire Human Genetic Therapies, Inc.
2018 Phase 3 EUCTR2017-003067-36-HU Canada;Denmark;Hungary;United States
2018 Phase 3 EUCTR2017-003067-36-DK Canada;Denmark;Hungary;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-SE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-PT Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-NO Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-ES Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-DK Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-BE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
Hydrochlorothiazide
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 2 EUCTR2016-000500-29-FR France
ICG
University Hospital, Brest
2021 Phase 3 NCT04785443 France
Immediate post operative bioassay OF parathyroid hormone
Centre Hospitalier Universitaire de Nimes
2012 - NCT02924532 -
Indocyanine green
Hospital Son Espases
2016 Phase 4 NCT04012476 Spain
Hospital Universitari Son Espases
2020 Phase 4 EUCTR2019-003506-26-ES Spain
IRCCS San Raffaele
2022 - NCT05328076 Italy
Indocyanine green near infrared fluorescence imaging
University Medical Center Groningen
2020 Early Phase 1 NCT06579430 Netherlands
Infracyanine
CHRU de Brest
2021 Phase 3 EUCTR2020-005189-32-FR France
INN parathyroid hormone (1-84) human
NPS Pharmaceuticals, Inc.
2015 Phase 1 EUCTR2015-003108-22-GB United Kingdom
Magnesium
University of Tartu
2009 - NCT00824226 Estonia
MBX 2109
MBX Biosciences
2024 Phase 2 NCT06465108 Argentina;United States
Methylene blue
The Sixth Medical Center of PLA General Hospital
2020 Phase 0 ChiCTR2300077263 China
Natpar
Shire Human Genetic Therapies, Inc.
2018 Phase 3;Phase 4 EUCTR2017-000284-32-SE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-PT Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-NO Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-DK Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-BE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
Natpara
Shire Human Genetic Therapies, Inc.
2018 Phase 3 EUCTR2017-003067-36-HU Canada;Denmark;Hungary;United States
2018 Phase 3 EUCTR2017-003067-36-DK Canada;Denmark;Hungary;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-IT Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-ES Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
Natpara/natpar
Entera Bio Ltd.
2018 Phase 2 NCT03516773 Israel
NEAR-infrared-induced autofluorescence and indocyanine green NEAR-infrared angiography
Odense University Hospital
2021 - NCT05130476 Denmark
Npsp 558
NPS PHARMACEUTICALS
2009 - EUCTR2008-005063-34-IT Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
NPS Pharmaceuticals, Inc.
2015 Phase 1 EUCTR2015-003108-22-GB United Kingdom
2011 - EUCTR2011-001265-40-HU Hungary
2010 - EUCTR2008-005063-34-LT Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2010 - EUCTR2008-005063-34-HU Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2009 Phase 3 EUCTR2008-005063-34-GB Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2009 Phase 3 EUCTR2008-005063-34-FR Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2009 - EUCTR2008-005063-34-DK Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2008 Phase 3 EUCTR2008-005063-34-BE Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
NPSP558
Shire
2011 Phase 3 NCT01455181 Hungary
2011 Phase 3 NCT01297309 United States
2011 Phase 3 NCT01268098 United States
2008 Phase 3 NCT00732615 Belgium;Canada;Denmark;France;Hungary;Italy;United Kingdom;United States
Ormone paratiroideo DA DNA ricombinante
Shire Human Genetic Therapies, Inc.
2018 Phase 3;Phase 4 EUCTR2017-000284-32-IT Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
Oxygen
Chongqing People's Hospital
2023 - ChiCTR2300076192 China
Palopegteriparatide
Ascendis Pharma Bone Diseases A/S
2022 - NCT05654701 -
2021 Phase 3 EUCTR2020-003380-26-HU Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2021 Phase 3 EUCTR2020-003380-26-DK Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2021 Phase 3 EUCTR2020-003380-26-DE Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2020 Phase 3 EUCTR2020-003380-26-NO Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-NO Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DK Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Parathyroid allotransplant
Peter Stock
2025 Phase 1/Phase 2 NCT06961071 United States
Parathyroid hormon 1-84
University of Bergen
2016 Early Phase 1 NCT02986607 Norway
Parathyroid hormone
Aarhus University Hospital, Dept of Endocrinology and Metabolism C
2008 Phase 4 EUCTR2008-000606-36-DK Denmark
Entera Bio Ltd.
2014 Phase 2 NCT02152228 Israel
NPS Pharmaceuticals, Inc.
2011 - EUCTR2011-001265-40-HU Hungary
2010 - EUCTR2008-005063-34-LT Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2010 - EUCTR2008-005063-34-HU Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2009 Phase 3 EUCTR2008-005063-34-GB Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2009 Phase 3 EUCTR2008-005063-34-FR Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2009 - EUCTR2008-005063-34-DK Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2008 Phase 3 EUCTR2008-005063-34-BE Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
Takeda Pharmaceutical Company Limited
2022 Phase 3 JPRN-jRCT2080224751 Japan
Parathyroid hormone (1-84) human recombinant
NPS Pharmaceuticals, Inc.
2015 Phase 1 EUCTR2015-003108-22-GB United Kingdom
Parathyroideahormon
Aarhus University Hospital, Dept of Endocrinology and Metabolism C
2008 Phase 4 EUCTR2008-000606-36-DK Denmark
PCO371
Chugai Pharmaceutical
2020 Phase 1 NCT04209179 Canada;Hungary;United States
Phosphate
Hokusetsu ROD Study Group
2006 - JPRN-UMIN000000475 Japan
Hospital Italiano de Buenos Aires
2016 Phase 4 NCT02652884 Argentina
Poly(OXY-1,2-ethanediyl), alpha-hydro-omega-methoxy, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-DI
Ascendis Pharma Bone Diseases A/S
2021 Phase 3 EUCTR2020-003380-26-HU Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2021 Phase 3 EUCTR2020-003380-26-DK Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2021 Phase 3 EUCTR2020-003380-26-DE Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2020 Phase 3 EUCTR2020-003380-26-NO Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
Poly(OXY-1,2-ethanediyl), alpha-hydro-omega-methoxy, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbon
Ascendis Pharma Bone Diseases A/S
2019 Phase 2 EUCTR2018-004815-33-NO Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Postoperative laboratory blood tests AT 24 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Postoperative laboratory blood tests AT 6 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Postoperative laboratory drainage fluid tests AT 24 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Postoperative nausea and vomiting AT 24 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Postoperative nausea and vomiting AT 6 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Postoperative pain AT 24 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Postoperative pain AT 6 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Postoperative sore throat and hoarseness AT 24 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Postoperative sore throat and hoarseness AT 6 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Potassium sparing diuretic
Assistance Publique - Hôpitaux de Paris
2017 Phase 2 NCT02824718 France
Preoparative blood laboratory tests
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Preotact
Aarhus University Hospital, Dept of Endocrinology and Metabolism C
2008 Phase 4 EUCTR2008-000606-36-DK Denmark
NPS Pharmaceuticals, Inc.
2011 - EUCTR2011-001265-40-HU Hungary
2010 - EUCTR2008-005063-34-LT Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
PTH
Columbia University
2009 Phase 3 NCT01199614 United States
John P. Bilezikian
2004 Phase 2/Phase 3 NCT00473265 United States
Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
2021 Phase 1-2 ChiCTR2100041719 China
University of Aarhus
2008 Phase 2 NCT00730210 Denmark
kawasaki medicak school
2009 Phase 3 JPRN-UMIN000002155 Japan
PTH 1-34
National Institute of Dental and Craniofacial Research (NIDCR)
2006 Phase 3 NCT00395538 Austria;Italy;United States
PTH based calcium carbonate and calcitriol repletion
CHU de Quebec-Universite Laval
2017 - NCT03249012 Canada
PTH1-84 IN parent study
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2010 Phase 3 NCT00856401 United States
Rhpth
NPS Pharmaceuticals, Inc.
2011 - EUCTR2011-001265-40-HU Hungary
2010 - EUCTR2008-005063-34-LT Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2010 - EUCTR2008-005063-34-HU Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2009 Phase 3 EUCTR2008-005063-34-GB Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2009 Phase 3 EUCTR2008-005063-34-FR Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2009 - EUCTR2008-005063-34-DK Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
2008 Phase 3 EUCTR2008-005063-34-BE Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
Shire
2022 Phase 3 NCT03878953 Japan
2018 Phase 3 NCT03364738 Canada;Denmark;Hungary;United States
2018 Phase 4 NCT03324880 Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2017 Phase 1 NCT03150108 United States
2017 Phase 1 NCT02781844 Canada;Denmark;Hungary;United States
2016 Phase 4 NCT02910466 United States
Shire Human Genetic Therapies, Inc.
2018 Phase 3 EUCTR2017-003067-36-HU Canada;Denmark;Hungary;United States
2018 Phase 3 EUCTR2017-003067-36-DK Canada;Denmark;Hungary;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-SE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-PT Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-NO Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-ES Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-DK Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
2018 Phase 3;Phase 4 EUCTR2017-000284-32-BE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
Takeda Pharmaceutical Company Limited
2022 Phase 3 JPRN-jRCT2080224751 Japan
Saline 0.9% nacl
Hospital Italiano de Buenos Aires
2016 Phase 4 NCT02652884 Argentina
Serum calcium concentrations results
Hospices Civils de Lyon
2019 - NCT04126941 France
Sevelamer
Hokusetsu ROD Study Group
2006 - JPRN-UMIN000000475 Japan
Sodium citrate
National Center for Research Resources (NCRR)
1995 - NCT00004361 -
Standard treatment according TO THE clinical protocols
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
2022 Phase 1/Phase 2 NCT05186883 -
SUB21634
Aarhus University Hospital, Dept of Endocrinology and Metabolism C
2008 Phase 4 EUCTR2008-000606-36-DK Denmark
Symptomatic hypocalcaemia AT 24 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Symptomatic hypocalcaemia AT 6 hour
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Synthetic human parathyroid hormone 1-34
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2008 Phase 2 NCT00743782 United States
1991 Phase 2 NCT00001304 United States
Teriparatide
Ascendis Pharma Bone Diseases A/S
2021 Phase 3 EUCTR2020-003380-26-HU Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2021 Phase 3 EUCTR2020-003380-26-DK Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2021 Phase 3 EUCTR2020-003380-26-DE Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2020 Phase 3 EUCTR2020-003380-26-NO Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-NO Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DK Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Assistance Publique - Hôpitaux de Paris
2017 Phase 2 NCT02824718 France
Dipartimento di Medicina e Chirurgia Traslazionale dell’Università degli Studi di Firenze
2014 Phase 3 EUCTR2013-001890-26-IT Italy
Mayo Clinic
2010 Phase 2 NCT01171690 United States
Saint Petersburg State University, Russia
2021 Phase 3 NCT04750460 Russian Federation
The Seventh Medical Center, PLA General Hospital
2021 - ChiCTR2100047758 China
Teriparatide conjugated TO A multiarm polyethylene glycol carrier molecule through A cleava
Ascendis Pharma Bone Diseases A/S
2021 Phase 3 EUCTR2020-003380-26-FR Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
Teriparatide conjugated TO A multiarm polyethylene glycol carrier molecule through A cleavable linker
Ascendis Pharma Bone Disease A/S
2021 Phase 3 EUCTR2020-003380-26-IT Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-IT Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Ascendis Pharma Bone Diseases A/S
2021 Phase 3 EUCTR2020-003380-26-FR Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-GB Canada;Denmark;Germany;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DE Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Thiazide
Assistance Publique - Hôpitaux de Paris
2017 Phase 2 NCT02824718 France
Thymus/parathyroid transplantation
M. Louise Markert
2005 Phase 1 NCT00566488 United States
Total thyroidectomy
Medical University of Lodz
2020 Phase 4 NCT04412694 Poland
Transcon PTH
Ascendis Pharma Bone Diseases A/S
2022 - NCT05654701 -
2021 Phase 3 EUCTR2020-003380-26-HU Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2021 Phase 3 EUCTR2020-003380-26-FR Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2021 Phase 3 EUCTR2020-003380-26-DK Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2021 Phase 3 EUCTR2020-003380-26-DE Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2020 Phase 3 EUCTR2020-003380-26-NO Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
Visen Pharmaceuticals (Shanghai) Co., Ltd.
2021 Phase 3 NCT05387070 China
Transcon PTH HIGH-dose PEN
Ascendis Pharma Bone Disease A/S
2021 Phase 3 EUCTR2020-003380-26-IT Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-IT Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Ascendis Pharma Bone Diseases A/S
2019 Phase 2 EUCTR2018-004815-33-NO Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-GB Canada;Denmark;Germany;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DK Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DE Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Transcon PTH LOW-dose PEN
Ascendis Pharma Bone Disease A/S
2021 Phase 3 EUCTR2020-003380-26-IT Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-IT Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Ascendis Pharma Bone Diseases A/S
2019 Phase 2 EUCTR2018-004815-33-NO Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-GB Canada;Denmark;Germany;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DK Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DE Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Transcon PTH MID-dose PEN
Ascendis Pharma Bone Disease A/S
2021 Phase 3 EUCTR2020-003380-26-IT Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-IT Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Ascendis Pharma Bone Diseases A/S
2019 Phase 2 EUCTR2018-004815-33-NO Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-GB Canada;Denmark;Germany;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DK Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
2019 Phase 2 EUCTR2018-004815-33-DE Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Tériparatide
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 2 EUCTR2016-000500-29-FR France
UN-alpha-R 0.25µG
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2016 Phase 2 EUCTR2016-000500-29-FR France
Vitamin D
University of Wisconsin, Madison
2005 Phase 4 NCT00581828 United States
West China Hospital, Sichuan University
2019 - ChiCTR1900022194 China